ANG Lifesciences India Share Price

CMP as on27-May-22 15:26

₹ 259.15
12.3 4.98%

Open

₹ 254.95

Turnover (lac)

₹ 131

Prev. Close

₹ 246.85

Day's Vol (shares)

₹ 32,629

Day's Range

₹ 252.00
₹ 259.15

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 23-Mar-2022 - -
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/03/2022 inter alia to consider and approve Pursuant to Regulation 25 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 (LODR) we hereby inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on March 31st 2022 at 03:30 PM at the Registered Office of the Company inter-alia to transact the following businesses: 1. To review the performance of Non-Independent Directors and the Board of Directors as a whole; 2. To review the performance of the Chairperson of the Company taking into account the views of executive directors and non-executive directors; 3. To assess the quality quantity and timeliness of flow of information between the management of the Company and the Board of Directors that is necessary for the Board of Directors to effectively and reasonably perform their duties; 4. To transact any other matter if any with permission of the Chair.
Board Meeting - 21-Mar-2022 - -
Inter-alia, to transact the following businesses: 1. Take note of necessary action as per the provision of para 4 of schedule B, read with regulation 9(1) and (2) of SEBI (PIT) Regulations 2015 against Mr. Pawanjit Singh, Non- Executive Independent Director of the Company as he unintentionally traded in 364 number of equity shares of ANG Lifesciences India Limited during the closure of trading window. 2. Re-constitution of Audit Committee; 3. Re-constitution of Stakeholder Relationship Committee; 4. Change in composition of CSR Committee; 5. Transact any other matter, if any with permission of the Chair. Pursuant to Regulation 30 (Listing Obligation and Disclosure Requirements) Regulations, 2015, this is to submit that the Board of Directors of the Company in its meeting held on today, Tuesday, 29-March-2022 has interalia, considered and approved the following matters as mentioned in the attachment. (As Per BSE Announcement dated on 29.03.2022)
Board Meeting - 05-Feb-2022 - -
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 (LODR) we hereby inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on February 14th 2022 at 04:30 PM at the Registered Office of the Company inter-alia to transact the following businesses: 1. To consider and approve the Unaudited Financial Results along with Limited Review Report thereon for the Quarter and Nine Months ended 31st December 2021; 2. To transact any other matter if any with permission of the Chair. Please take the same on your record Pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on Monday, 14th February, 2022 has considered and approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine month ended December 31, 2021 along with the Limited Review Report thereon issued by M/s Raman Wadhwa & Co., Statutory Auditors of the Company. Pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on Monday, 14th February, 2022 has considered and approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine month ended December 31, 2021 along with the Limited Review Report thereon issued by M/s Raman Wadhwa & Co., Statutory Auditors of the Company. (As per BSE Announcement Dated on 14/02/2022)
Board Meeting - 24-Nov-2021 - -
Pursuant to Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements), 2015, we would like to inform you that the Companys Board of Directors in their meeting held on 23-Nov-2021, has decided to invest in the equity shares of ANG Healthcare India Private Limited. Therefore consequent to the acquisition of 100% Equity stake by the company, ANG Healthcare India Private Limited will become Wholly-Owned Subsidiary Company of ANG Lifesciences India Limited. ANG Healthcare India Private Limited is a marketing company selling critical care products to Hospitals and Nursing Homes in therapeutic segments of anti-biotic, anti-infective, anti-malarial, pain management etc. The company has got presence all over India through a network of Super Stockists and 150 Stockists along with a strong sales force of about 60 personnel and expanding at a fast pace.
Board Meeting - 01-Oct-2021 - -
Half Yearly Results & A.G.M. & Dividend ANG Lifesciences India Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on October 25, 2021, inter alia, to transact the following business: 1. To consider and approve the Unaudited Financial Result for the half year ended September 30, 2021. 2. To consider the proposal for payment of Interim Dividend on the equity shares of the Company for financial year 2021-22. 3. To decide the date, day & time of Annual General Meeting for the financial year 2020-21. (As Per BSE announcement Dated on 01.10.2021) ANG Lifesciences India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 25, 2021, inter alia, has declared an Interim Dividend of Rs. 1/- per Equity Shares (10% on the face value of Rs. 10/- each). This is the first Interim Dividend declared by the Board for the Financial Year 2021-22. Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015, this is to submit that the Board of Directors of the Company in its meeting held on today, Monday, 25-Oct- 2021 has, interalia, considered and approved the matters as discussed in the Board meeting. Please find attached herewith the documents. Outcome of Board Meeting dated 25.10.2021 along with half yearly financial result -30.09.2021 (As Per BSE Announcement Dated on 25.10.2021)
Board Meeting - 24-Sep-2021 - -
Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, this is to inform you that Board of Directors of the Company on 24th September, 2021 has allotted 51,83,315 Equity Shares having face value of Rs.10 each as Fully-Paid up Bonus shares in the ratio of 1:1 i.e. 1 (One) new fully paid-up equity shares each for every 1 (One) existing fully paid -up equity shares of Rs. 10 each to all the eligible members of the Company, whose name appear in the Register of members/list of beneficiary owners as on 23.09.2021 (being the record date fixed for this purpose).
Board Meeting - 30-Jul-2021 - -
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 ,inter alia, to consider and approve Pursuant to the Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, It is hereby informed you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, August 06th, 2021 at 03:30 P.M. at the Registered Office of the Company situated at Darbara Complex, SCO-113, District Shopping Centre, B Block, Ranjit Avenue, Amritsar-143001, inter alia transact the following business: 1. To consider and approve Increase in Authorised Share Capital of the Company. 2. To consider and approve the Issue of Bonus Shares. 3. To consider and approve the Migration of the Company from BSE SME Platform to Main Board of BSE Limited. 4. Any other business that may be necessary with the permission of Chairman. Please take the same on your record. In continuation to our earlier intimation dated July 30th, 2021 for the meeting of Board of Directors of the Company scheduled to be held on Friday, 6th, August 2021 at 3:30 P.M. we would like to inform you that as per the SEBI (Prohibition of Insider Trading) Regulation, 2015 as amended from time to time and the Companys Code of Conduct to regulate, monitor and report the trading of equity shares, the Trading Window for dealing in the securities of the company by the designated persons and their immediate relatives of the company has already been closed from 30th July, 2021 and shall remain closed till 48 hours from the closure of the Board Meeting. Please take the same on your record. (As Per BSE Announcement Dated on 31/07/2021) Board recommends Bonus Issue Approved the Issuance of fully paid up Bonus Shares in the ratio of One (1) Fully paid up share for every One (1) fully paid up shares held, subject to shareholders approval by way of Postal Ballot Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015, this is to submit that the Board of Directors of the Company in its meeting held on today, Friday, 06th August, 2021 has, interalia, considered and approved the following matter as per attchment attached Board recommends Bonus Issue (As Per BSE bulletin Dated on 06.08.2021)
Board Meeting - 24-Jul-2021 - -
Pursuant to regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors in its meeting held i.e. 24.07.2021 at 04:00 P.M. has decided to make the investment of Rs. 1.00 cores in a startup healthcare company-Renatus Meditech Solutions Pvt. Ltd. as a seed investor for 10% stake. It is also pertinent to mention here that Renatus Meditech Solutions Pvt. Ltd. which is recognized as a Healthcare Startup by the Department for promotion of Industry and Internal Trade (DPIT), Ministry of Commerce & Industry, Government of India. We would also like to add that we would prefer to build on our relationship with Renatus Meditech Solution Pvt. Ltd. for next stage investing also as an angel investor. The Brief profile of M/s Renatus Meditech Solutions Pvt. Ltd. is enclosed as Annexure -I Kindly take the same on your record.
Board Meeting - 24-Jun-2021 - -
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/06/2021 ,inter alia, to consider and approve Standalone Audited Financial Results of the Company for the Half Year and Financial Year ended as on 31st March, 2021 at 03:30 P.M. at the Registered Office of the Company situated at Darbara Complex, SCO-113, District Shopping Centre, B Block, Ranjit Avenue, Amritsar-143001 and to discuss any other business matter with the permission of Chair. Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on June 30, 2021 has inter-alia considered and approved the Standalone Audited Financial Results of the Company for the half year and financial year ended March 31, 2021 along with the Auditors Report thereon received from M/s Raman Wadhwa & Co., Statutory Auditors of the Company and declaration pursuant to Reg. 33(3)(d) of Listing Regulations. The Board Meeting was commenced at 3:30 P.M and concluded at 5:15 P.M. This is for your information. Kindly take the same on your record. (As Per BSE Announcement dated on 30.06.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity